Multiple surveys of patient-reported outcomes from the phase 3 EMBARK trial revealed no meaningful differences in pain progression or urinary symptoms and bowel symptoms or function over 205 weeks of follow-up. Enzalutamide does not worsen health-related quality of life compared with androgen deprivation therapy in patients with high-risk biochemically recurrence nmCSPC.
The FDA has approved capivasertib plus fulvestrant for the treatment of patients with HR-positive, HER2-negative, locally advanced or metastatic breast cancer harboring 1 or more PIK3CA, AKT1, or PTEN alteration, following progression on at least 1 endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.
Operator: Thank you for standing by and welcome to the Natera Inc. Q3 Earnings Conference Call. All lines have been placed on mute to prevent any background noise.
Potential First-in-Class Tetravalent Bispecific Antibody Demonstrates Enhanced Binding in the Simultaneous Presence of PD-1 & VEGF Cooperative Binding of Ivonescimab Enables Higher Avidity in the Tumor Microenvironment with Over 18 Fold Increased Binding Affinity to PD-1 in the Presence of VEGF in vitro HONG KONG, Nov. 2, 2023 /PRNewswire/ Akeso (9926.HK) today announced that its collaboration and licensing.